哮喘嗜酸性气道炎症挥发性标志物特征的发现与验证
研究通过痰液顶空GC-MS在36例重症哮喘患者中鉴定19种与痰嗜酸粒细胞增多相关的挥发性有机化合物(VOC)并构建标志物特征,随后在英国EMBER队列(n=65)和U-BIOPRED队列(n=42)的呼出气样本中验证,该特征对痰嗜酸粒细胞≥3%及急性哮喘发作显示出良好诊断准确性,优于呼出气一氧化氮。
要点
- 痰液顶空VOC特征对痰嗜酸粒细胞≥3%的AUROC为0.90,优于FeNO的0.61。
- 呼出气VOC特征在EMBER和U-BIOPRED队列中AUROC分别为0.89和0.90。
- 该VOC特征与痰嗜酸粒细胞百分比呈负相关(rs=-0.71)。
核心结论
- 发现并初步临床验证了与嗜酸性气道炎症相关的挥发性生物标志物特征。
- 该VOC特征在多个队列中诊断准确性良好,优于呼出气一氧化氮。
- 需进一步工作利用即时临床传感器转化该发现。
研究设计与样本
- 研究在36例重症哮喘患者中收集痰液顶空VOC,用热脱附气相色谱-质谱联用(GC-MS)分析。
- 采用弹性网回归识别与痰嗜酸粒细胞≥3%相关的稳定VOC并生成标志物特征。
- 在英国EMBER队列(n=65)和U-BIOPRED队列(n=42)的呼出气样本中验证该特征。
主要发现
- 痰液顶空鉴定出19种与痰嗜酸粒细胞增多相关的VOC。
- VOC特征对痰嗜酸粒细胞≥3%的AUROC为0.90(95%CI 0.80-0.99;P<0.0001)。
- VOC特征与痰嗜酸粒细胞百分比呈负相关(rs=-0.71;P<0.0001)。
- VOC特征优于呼出气一氧化氮(AUROC 0.61;95%CI 0.35-0.86)。
- 呼出气VOC特征对急性哮喘发作的AUROC在EMBER队列为0.89(95%CI 0.76-1.0),在U-BIOPRED为0.90(95%CI 0.75-1.0)。
关键数值与推荐
- 痰嗜酸粒细胞增多定义为痰嗜酸粒细胞≥3%。
- 急性哮喘根据血嗜酸粒细胞≥0.3×10^9 cells/L或痰嗜酸粒细胞≥3%定义。
- U-BIOPRED中VOC特征优于呼出气一氧化氮(AUROC 0.62;95%CI 0.33-0.90)。
临床怎么用
- 该VOC特征有望作为无创标志物预测哮喘患者痰嗜酸粒细胞增多。
- 在临床应用中可能辅助识别嗜酸性气道炎症,指导抗炎治疗。
- 目前尚需开发即时临床传感器以实现转化应用。
局限性
- 研究为早期临床验证,样本量有限。
- 需进一步工作利用即时临床传感器转化发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. Methods: VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (n = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: 1) patients with acute asthma according to blood eosinophilia ⩾0.3 × 109cells/L or sputum eosinophilia of ⩾3% in the UK EMBER (East Midlands Breathomics Pathology Node) consortium (n = 65) and 2) U-BIOPRED-IMI (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes Innovative Medicines Initiative) consortium (n = 42). Breath samples were collected onto sorbent tubes (EMBER) or Tedlar bags (U-BIOPRED) and analyzed by GC-MS (GC × GC-MS for EMBER or GC-MS for U-BIOPRED). Measurements and Main Results: The in vitro headspace identified 19 VOCs associated with sputum eosinophilia, and the derived VOC signature yielded good diagnostic accuracy for sputum eosinophilia ⩾3% in headspace (area under the receiver operating characteristic curve [AUROC] 0.90; 95% confidence interval [CI], 0.80-0.99; P < 0.0001), correlated inversely with sputum eosinophil percentage (rs = -0.71; P < 0.0001), and outperformed fractional exhaled nitric oxide (AUROC 0.61; 95% CI, 0.35-0.86). Analysis of exhaled breath in replication cohorts yielded a VOC signature AUROC (95% CI) for acute asthma exacerbations of 0.89 (0.76-1.0) (EMBER cohort) with sputum eosinophilia and 0.90 (0.75-1.0) in U-BIOPRED, again outperforming fractional exhaled nitric oxide in U-BIOPRED (0.62 [0.33-0.90]). Conclusions: We have discovered and provided early-stage clinical validation of a volatile biomarker signature associated with eosinophilic airway inflammation. Further work is needed to translate our discovery using point-of-care clinical sensors.
引用
- Peltrini R, Cordell RL, Wilde M, et al. Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma. Am J Respir Crit Care Med. 2024. PMID: 38820123. doi:10.1164/rccm.202310-1759OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。